Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy

Area of Science:

• Pharmacology
• Respiratory Medicine
• Drug Delivery Systems

Background:

• Inhaled antimicrobials are a promising alternative for lung infections, offering higher local concentrations and reduced systemic exposure.
• This approach allows for the use of antimicrobials with severe systemic side effects.
• However, the inhalation route presents unique challenges in pharmacokinetic (PK) and pharmacodynamic (PD) assessments.

Purpose of the Study:

• To review the challenges in PK/PD assessments of inhaled antimicrobials.
• To discuss considerations for study design, data analysis, and interpretation.
• To highlight advancements that overcome these challenges.

Main Methods:

• Literature review of pharmacokinetic and pharmacodynamic assessments for inhaled antimicrobials.
• Discussion of challenges in drug delivery, absorption, distribution, metabolism, and excretion in the lungs.
• Analysis of methods for PK/PD data interpretation specific to inhaled therapies.

Main Results:

• Inhalation offers targeted delivery but complicates PK/PD analysis due to complex lung physiology.
• Standard PK/PD models may require adaptation for inhaled antimicrobials.
• Several advancements are emerging to improve the assessment and optimization of inhaled antimicrobial therapy.

Conclusions:

• Optimizing PK/PD assessment is crucial for maximizing the efficacy of inhaled antimicrobials.
• Addressing the unique challenges of inhalation is key to developing effective inhaled antimicrobial strategies.
• Further research and methodological advancements will enhance the clinical application of inhaled antimicrobials.